

NHS Borders
Education Centre
Borders General Hospital
Melrose
Roxburghshire
TD6 9BD
01896 825545
foi.enquiries@borders.scot.nhs.uk



Freedom of Information request 70-18

Request & Response

I have a Freedom of Information request regarding Ovarian and Prostate treatments. Within your Organisation in the last 12 months – latest that you have available.

1 - How many Ovarian Carcinoma patients (any stage) have been diagnosed in the last 12 months?

The latest data available is from 2016 and this was 9 patients.

2 – How many stage III or IV Ovarian Carcinoma patients have received Chemotherapy for the first time in the last 12 months?

5 patients

Of these how many patients are on Platinum based therapy (Monotherapy or combination therapy)?

<5 patients

3 – How many stage III or IV Ovarian Carcinoma patients have been diagnosed as Platinum refractory (ie progression of disease whilst receiving Platinum therapy) or resistant (ie progression of disease within 6 months of last Platinum dose) in the last 12 months?

<5 patients

4 – How many patients with Stage III or IV Ovarian Carcinoma have been treated with the following treatments in the last 12 months?

Of those how many are Platinum refractory or Platinum resistant?

Treatments	Stage III or IV patients (total number)	Number of Stage III or IV Platinum refractory OR Platinum resistant patients
Total Patients	7	14
PEG Liposomal Doxorubicin (Caelyx)	< 5	<5
Gemcitabine	0	0
Paclitaxel	6	13
Docetaxel	0	0
Bevacizumab	<5	<5
Topotecan	0	0
Clinical trial therapy	0	0
Other – please specify		

5 – Within your Organisation how many patients with Advanced Prostate Cancer have been treated in the past 12 months with the following treatments?

Treatment	Patients
Abiraterone (Zytiga)	0
Cabazitaxel (Jevtana)	<5
Docetaxel (Taxotere)	18
Enzalutamide (Xtandi)	0
Radium-223 (Xofigo)	0

6 – How many patients being treated with Abiraterone or Enzalutamide and have been on this treatment for more than 1 year?

NHS Borders do not hold this data as all patients treated with Abiraterone or Enzalutamide are treated in NHS Lothian. Therefore under Section 17 of the FOI(S)A 2002 this data is not held.

As the number of events in some areas are very small and in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the ISD Statistical Disclosure Control Protocol.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **70-18** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.